About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2019
2018
2017
2016
2015
2014
2013
2012
Oct 25, 2016 7:15 AM EDT
Can-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea
Oct 13, 2016 7:00 AM EDT
Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH
Sep 20, 2016 7:00 AM EDT
Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal
Sep 13, 2016 7:00 AM EDT
Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial
Sep 7, 2016 7:00 AM EDT
Can-Fite to Present at Rodman & Renshaw Conference in New York City on September 12, 2016
Aug 26, 2016 7:00 AM EDT
Can-Fite Reports Financial Results for Six Months Ended June 30, 2016
Aug 8, 2016 7:00 AM EDT
Can-Fite's Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology
Jul 25, 2016 7:00 AM EDT
Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD
Jul 5, 2016 7:00 AM EDT
OphthaliX Announces Phase II Glaucoma Data
Jun 15, 2016 7:00 AM EDT
Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects
<< Previous
1...
5
6
7
8
9
10
11
12
13
14
...23
Next >>
Show All
